In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $30.00. The company’s shares closed last Friday at $11.83.
Tsao covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Praxis Precision Medicines, and Roivant Sciences. According to TipRanks, Tsao has an average return of 2.0% and a 40.10% success rate on recommended stocks.
Currently, the analyst consensus on Coherus Biosciences is a Moderate Buy with an average price target of $18.21, implying a 53.93% upside from current levels. In a report released on August 2, Mizuho Securities also assigned a Buy rating to the stock with a $25.00 price target.
CHRS market cap is currently $915.9M and has a P/E ratio of (3.98).
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS:
- Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Keeps Their Buy Rating on Alector (ALEC)
- H.C. Wainwright Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
- H.C. Wainwright Sticks to Its Buy Rating for Akero Therapeutics (AKRO)
- H.C. Wainwright Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)